Basit öğe kaydını göster

Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo

dc.contributor.authorSolomon, Scott D.
dc.contributor.authorWu, Yujun
dc.contributor.authorPfeffer, Marc A.
dc.contributor.authorClaggett, Brian
dc.contributor.authorDiaz, Rafael
dc.contributor.authorDickstein, Kenneth
dc.contributor.authorGerstein, Hertzel C.
dc.contributor.authorJohnston, Peter
dc.contributor.authorKober, Lars V.
dc.contributor.authorLawson, Francesca
dc.contributor.authorLewis, Eldrin F.
dc.contributor.authorMaggioni, Aldo P.
dc.contributor.authorMcMurray, John J. V.
dc.contributor.authorPing, Lin
dc.contributor.authorProbstfield, Jeffrey L.
dc.contributor.authorTardif, Jean-Claude
dc.contributor.authorBentley-Lewis, Rhonda
dc.contributor.authorAguilar, David
dc.contributor.authorRiddle, Matthew C.
dc.date.accessioned2022-02-18T09:38:04Z
dc.date.available2022-02-18T09:38:04Z
dc.date.issued2015
dc.identifier.citationBentley-Lewis R., Aguilar D., Riddle M. C. , Claggett B., Diaz R., Dickstein K., Gerstein H. C. , Johnston P., Kober L. V. , Lawson F., et al., "Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo", AMERICAN HEART JOURNAL, cilt.169, sa.5, ss.631-645, 2015
dc.identifier.issn0002-8703
dc.identifier.othervv_1032021
dc.identifier.otherav_4e9acc2c-338b-4e44-b0a6-304178259d08
dc.identifier.urihttp://hdl.handle.net/20.500.12627/177617
dc.identifier.urihttps://doi.org/10.1016/j.ahj.2015.02.002
dc.description.abstractBackground Cardiovascular (CV) disease is the leading cause of morbidity andmortality in patients with type 2 diabetes mellitus (T2DM). Furthermore, patients with T2DM and acute coronary syndrome (ACS) have a particularly high risk of CV events. The glucagon-like peptide 1 receptor agonist, lixisenatide, improves glycemia, but its effects on CV events have not been thoroughly evaluated.
dc.language.isoeng
dc.subjectKlinik Tıp (MED)
dc.subjectDahili Tıp Bilimleri
dc.subjectKardiyoloji
dc.subjectCardiology and Cardiovascular Medicine
dc.subjectHealth Sciences
dc.subjectCARDIAC ve CARDIOVASCULAR SİSTEMLER
dc.subjectKlinik Tıp
dc.subjectSağlık Bilimleri
dc.subjectTıp
dc.titleRationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo
dc.typeMakale
dc.relation.journalAMERICAN HEART JOURNAL
dc.contributor.departmentHarvard University , ,
dc.identifier.volume169
dc.identifier.issue5
dc.identifier.startpage631
dc.identifier.endpage645
dc.contributor.firstauthorID3383233


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster